Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore(University Health Network), Wendy R. Parulekar(Unknown), Steven Gallinger(Ontario Institute for Cancer Research), Mieke Ptasynski(Ontario Institute for Cancer Research), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), John Hamm(Ontario Institute for Cancer Research), P. Murawa(Ontario Institute for Cancer Research), David Walde(Ontario Institute for Cancer Research), Daniel de Castro(Ontario Institute for Cancer Research), Theodora Voskoglou-Nomikos(Ontario Institute for Cancer Research), Gary M. Clark(Dana-Farber Brigham Cancer Center), Arié Figer(Ontario Institute for Cancer Research), Robert Lim(Ontario Institute for Cancer Research), J. Randolph Hecht(Ontario Institute for Cancer Research), Keyue Ding(Ontario Institute for Cancer Research), H. Au(Ontario Institute for Cancer Research), David Goldstein(New South Wales Department of Health)
Cited by 3,856
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k